posted on 2024-07-10, 05:30authored byMads K. Skaanning, Jonas Bønnelykke, Minke A. D. Nijenhuis, Anirban Samanta, Jakob Melgaard Smidt, Kurt V. Gothelf
The
primary challenge of implementing DNA nanostructures
in biomedical
applications lies in their vulnerability to nuclease degradation and
variations in ionic strength. Furthermore, the size minimization of
DNA and RNA nanostructures is limited by the stability of the DNA
and RNA duplexes. This study presents a solution to these problems
through the use of acyclic (l)-threoninol nucleic acid (aTNA),
an artificial acyclic nucleic acid, which offers enhanced resilience
under physiological conditions. The high stability of homo aTNA duplexes
enables the design of durable nanostructures with dimensions below
5 nm, previously unattainable due to the inherent instability of DNA
structures. The assembly of a stable aTNA-based 3D cube and pyramid
that involves an i-motif formation is demonstrated. In particular,
the cube outperforms its DNA-based counterparts in terms of stability.
We furthermore demonstrate the successful attachment of a nanobody
to the aTNA cube using the favorable triplex formation of aTNA with
ssDNA. The selective in vitro binding capability to human epidermal
growth factor receptor 2 is demonstrated. The presented research presents
the use of aTNA for the creation of smaller durable nanostructures
for future medical applications. It also introduces a new method for
attaching payloads to these structures, enhancing their utility in
targeted therapies.